Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Shares Down 4.1% – Here’s Why

Cosmo Pharmaceuticals (OTCMKTS:CMOPF) shares were down 4.1% during mid-day trading on Monday . The stock traded as low as C$68.07 and last traded at C$68.50. 2,112 shares changed hands during trading, an increase of 450% from the average daily volume of 384 shares. The stock had previously closed at C$71.42.

Cosmo Pharmaceuticals Stock Down 2.6%

The business has a 50 day moving average of C$77.03 and a 200 day moving average of C$99.70.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.